Link copied to clipboard!

Ayushman Yojana results in significant reduction of out-of-pocket expenditure: Economic Survey

IMT News Desk
IMT News Desk
· 4 min read

Over Rs 1.25 lakh crore savings recorded

The Economic Survey 2024-25 tabled in Parliament today talked about government initiatives, including preventive measures, universal access to high-quality healthcare, strengthened public health infrastructure, and advancements in medical education, which have collectively contributed to making healthcare in India more accessible and affordable for all.

As per the Economic Survey, the Total Health Expenditure (THE) in FY22 is estimated to be Rs 9,04,461 crore (3.8 per cent of GDP and Rs 6,602 per capita at current prices). Total Health Expenditure per capita (at constant prices) has shown an increasing trend since FY19.

In the total health expenditure of the country between FY15 and FY22, the share of government health expenditure has increased from 29.0 per cent to 48.0 per cent.

Out of THE, the current health expenditure (CHE) is Rs 7,89,760 crore (87.3 per cent of THE), and capital expenditure is Rs 1,14,701 crore (12.7 per cent of THE). An increase in the share of capital expenditure in THE from 6.3 per cent in FY16 to 12.7 per cent in FY22 is a positive sign as it will lead to broader and better health infrastructure.

The AB-PMJAY has revolutionised healthcare by providing health coverage to the bottom 40 per cent of India’s most vulnerable populations.

The increase in government spending on health has an important implication for the reduction of financial hardship endured by households

As of January 15, 2025, more than 40 lakh senior citizens have been enrolled in the scheme.

AB-PMJAY has played a decisive role in the significant reductions observed in Out-of-pocket expenditure (OOPE) through an increase in social security and primary health expenditure, with over Rs 1.25 lakh crore in savings recorded.

Other initiatives, such as the Free Dialysis scheme, have benefited around 25 lakh people. The reduction in OOPE goes hand in hand with increased public spending on healthcare, demonstrating progress towards universal health coverage.

Under the scheme, by transforming sub-health centres (SHCs) and primary health centres (PHCs), Ayushman Arogya Mandirs (AAM) (formerly Health & Wellness Centres) have been operationalised, in rural and urban areas, offering a universal, free, and expanded package of preventive, promotive, curative, palliative, and rehabilitative services closer to communities.

The Economic Survey has highlighted that under Ayushman Bharat Digital Mission (ABDM) 72.81 crore Ayushman Bharat health Accounts have been created.

It has also highlighted that E-Sanjeevani – the National Telemedicine Service, has emerged as the world’s largest telemedicine implementation in primary healthcare. It has served over 31.19 crore patients through 1.29 lakh AAM as spokes, which are served by 16,447 hubs and 676 online OPDs.

The Economic Survey further states that on the U–WIN portal over 1.7 crore pregnant women and 5.4 crore children have registered digitally and tracked more than 26.4 crore vaccine doses in real-time.

Economic Survey points out that Drones are transforming healthcare in India by ensuring rapid delivery of life-saving medicines and collecting samples from remote and inaccessible areas, proving indispensable during emergencies.

The project ‘i-DRONE’ was launched under the aegis of the MoHFW in October 2021 with the view to assess the feasibility of using drones to deliver vaccines and medical supplies.

The Economic Survey says that India has great potential for Artificial Intelligence adoption in Healthcare. It also stated that in 2023, 34 per cent of healthcare organisations in India were piloting AI projects, and 16 per cent had moved their generative AI initiatives into production.

The Economic Survey 2024-25 states that with full immunisation coverage for FY24 at 93.5 per cent nationally, the Univeral Immunisation Programme continues to safeguard public health and ensure equitable access to essential vaccines. A child who has received Bacille Calmette Guerin (BCG), three doses of Oral Polio Vaccine (OPV), three doses of Pentavalent and one dose of Measles Rubella (MR) by the first year of age is called a fully immunised child.

The survey also states that the Jan Aushadhi scheme, launched to provide affordable medicines, has improved access to low-cost drugs achieving record sales in 2024 and expanding to over 14,000 kendras nationwide.

PIB

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk